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Introduction
Excessive unbalanced production of reactive oxygen species (ROS), namely superoxide anion radical (O 2 -. ), singlet oxygen ( 1 O 2 ), hydroxyl radical ( . OH) and hydrogen peroxide (H 2 O 2 ), has been well established to be associated with many pathological conditions including atherosclerosis, stroke, diabetes, Alzheimer's disease, cancer and inflammation 1 . In a counter action and to maintain homeostasis, living cells combat the deleterious effects of ROS by an arsenal of biochemical antioxidants. 2, 3 . Under oxidative stress conditions; where the balance between ROS and biochemical antioxidants is lost due to over production of the former or under availability of the latter; ROS can attack and damage cellular membrane lipids, DNA nucleotides 4 , proteins' sulphydryl groups 5 and ribonucleoproteins 6 . Among the most important antioxidant mechanisms activated under conditions of oxidative stress is the Kelch-like ECH-associated protein 1 (Keap1)nuclear factor erythroid 2-related factor 2 (Nrf2)-antioxidant response elements (AREs) pathway 7 . This pathway is associated with the expression of more than 100 cytoprotective genes and their respective enzymes, one of which is NAD(P)H:quinone oxidoreductase 1 (NQO1, EC 1.6.99.2). Under homeostatic conditions, Nrf2 is continuously targeted for ubiquitination and proteasomal degradation by Keap1.
However, upon increased oxidative load, reactive cysteine residues within Keap1 serve as sensors for oxidants, leading to loss of its ability to target Nrf2 for degradation, subsequent accumulation of the transcription factor, activation of the pathway and increased transcription of cytoprotective antoxidant proteins [8] [9] [10] .
Medicinal chemists view the Keap1-Nrf2 protein-protein interaction as a critical point of the pathway that can be targeted for intervention and for potential management of a variety of oxidative stress-related ailments like cancer, Parkinson's, Alzheimer's and diabetes [11] [12] [13] [14] . Design of non-covalent small molecule modulators of the Keap-Nrf2
interaction has been widely explored 15, 16 . Quinazoline-based nitrogenous heteroaryls 3 are an excellent reservoir of bioactive substances where a number of biological activities have been associated with antioxidant activity [17] [18] [19] .
In continuation of our quest for new cytoprotective agents 20, 21 , we herein report the synthesis, NQO1 inducer activity and Keap1 inhibitory in silico screening results for a novel class of N-aryl substituted 4-amino-2-phenylquinazolines.
Materials and Methods

Chemistry
Melting 
Biological evaluation
Hepa1c1c7 murine hepatoma cells were maintained in a humidified atmosphere at 37 o C, 5% CO prepared in digitonin and the specific activity of NQO1 was determined using menadione as a substrate as previously described 22 . The Concentration which Doubles the specific activity of NQO1 (CD value) was used as a measure of inducer potency. 8 Mean values for the eight replicate wells are shown for each data point. The standard deviation for each data point was within 5% of the value.
Molecular modeling study
The 3D molecular models of the newly synthesized phenylquinazolinamine derivatives 4IQK). The protein target was prepared for docking by addition of the missing hydrogens and calculating the partial charges. Internal validation was performed to the native ligand followed by docking of the compounds where the target protein was kept rigid, while ligands were allowed to rotate to accommodate freely inside the protein cavity.
Following multiple separate docking simulations using default parameters, the best conformations were chosen based on the combination of S score data, E conformation and appropriate fitting with the relevant amino acids in the binding pocket.
Results and discussion
Chemistry
The aim of this work was to design and synthesize a novel series of quinazolines bearing biologically active heterocyclic moieties to evaluate and explore their NQO1 inducer activity. Therefore revealed the presence of a singlet at 6.2 ppm for the chromene CH group. 13 C-NMR spectrum of compound 11 showed signals at 112.6, 123.5 and 160.7 ppm for CH chromene, CF 3 and C=O groups, respectively. 1 H-NMR spectrum of compound 12
revealed the presence of a multiplet at 2.8-3.7 ppm for the morpholino 4CH 2 groups. 13 C-NMR spectrum of compound 12 showed signals at 49.2, 66.6 ppm corresponding to the CH 2 -N-CH 2 and the CH 2 -O-CH 2 morpholino 4CH 2 groups, respectively.
Biological evaluation
NQO1 inducer activity assessment represented in Figure 1 and Table 1 revealed that while the dihydroindenyl derivative 2 was devoid of NQO1 inducer activity, its dioxo 
Molecular modeling study
Keap1 is known to bind to Nrf2 promoting its degradation, resulting in low levels of cytoprotective gene products. Various small molecule compounds were reported to bind to the Keap1 Kelch domain and antagonize its activity 23, 24, 25 . For assessing the newly synthesized compounds' ability to access and block the Kelch domain of Keap1, a molecular docking study was performed using the Keap1 crystal coordinates obtained from the Protein Data Bank (PDB ID: 4IQK). The main interactions observed between the validated native ligand and the protein target were found to be arene-cation interaction with Arg415, arene-arene interaction with Tyr525 and 3 hydrogen bonds with Ser602, Ser508 and Ser555 with S = -13.306 Kcal/mol and rmsd 0.6635 Kcal/mol/Å (Figure 2 ).
Upon docking of the synthesized compounds, they all showed an arene-cation binding interaction with Arg415 via their aromatic rings. Compound 11 (S= -10.913 Kcal/mol) has adopted a conformation allowing the presence of 3 arene-cation interactions with
Arg415 and multiple rings of the ligand (Figures 3 and 4 ). One limitation of our study is the lack of a well-established biological assay for assessing the ability of small molecules to disrupt the Keap1-Nrf2 protein-protein interactions.
Therefore, although the molecular docking study suggests that these compounds can potentially bind to Keap1 and disrupt its interaction with Nrf2, further experimental 17 evidence is required to confirm this possibility. Regardless of the precise mode of action in activating Nrf2, the inducer potency of compound 7 in upregulating NQO1 strongly suggests that this compound could be used as a lead for further optimization of the quinazoline scaffold.
Conclusion
In conclusion, this study presents the synthesis of N-substituted 2-phenylquinazolin-4amine based derivatives 2-12 as cytoprotective NQO1 inducers. The most potent inducer in this study was the analogue 7 which caused a dose-dependent induction of NQO1 with a CD value of 0.4 μM. In silico evaluation of these derivatives as Keap1-Nrf2 protein-protein interaction inhibitors was performed using molecular docking techniques employing MOE software version 10.2009. Derivatives were found to bind to key amino acids in the binding site with a network or arene-arene and arene-cationic interactions. These molecules represent promising quinazoline scaffold-based leads for further optimization as cytoprotective agents and for future investigations into other plausible modes of action.
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